Evaluation of miRNA-21 and miRNA-155 expressions in Breast Carcinoma: Promising diagnostic tumor markers
DOI:
https://doi.org/10.22317/jcms.v12i2.2110Keywords:
miRNA-21, miRNA-155, Breast Carcinoma, Tumor Biomarkers, Diagnostic MarkersAbstract
Objective: This study aimed to evaluate the expression of miRNA-21 and miRNA-155 in breast cancer in patients as well as their potential value as molecular biomarkers in Duhok city, Kurdistan region Iraq.
Methods: The levels of miRNA-21 and miRNA-155 were assessed in pre-operative sera, neoplastic and non-neoplastic tissue samples from breast cancer patients and the sera of healthy controls using quantitative real-time PCR (qRT-PCR). Relative expression was calculated. Receiver operating characteristic (ROC) curve analysis was done for testing the diagnostic accuracy of each miRNA separately and together.
Results: Both miRNA-21 and miRNA-155 were significantly upregulated in sera of cancer patients compared to control sera and neoplastic tissue compared to adjacent non-neoplastic tissue (sera P-value:0.002, ≤ 0.0001, tissue P. value: 0.015 and≤ 0.001 respectively). ROC curve analysis demonstrated good diagnostic performance for each miRNA-21 and miRNA-155 in sera (89.7, 82.8; 70, 90% respectively) and tissue (96.4,50; 42,100% respectively).
Conclusion: The significant overexpression of both biomarkers in sera sample in compare to controls, and neoplastic in compare to non-neoplastic tissues supports their potential role as diagnostic biomarkers; however, these two combined analyses may provide a more accurate non-invasive approach to early detection of breast cancer.
References
Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029-30.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209-49.
Musa DH. Hormonal receptor status and lymph nodes involvement in breast cancer: a retrospective study : Hormones and lymph nodes in breast cancer. Cellular and Molecular Biology. 2025;71(8):67-71.
Bautista-Sánchez D, Arriaga-Canon C, Pedroza-Torres A, De La Rosa-Velázquez IA, González-Barrios R, Contreras-Espinosa L, et al. The Promising Role of miR-21 as a Cancer Biomarker and Its Importance in RNA-Based Therapeutics. Mol Ther Nucleic Acids. 2020;20:409-20.
Khalighfard S, Alizadeh AM, Irani S, Omranipour R. Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients. Scientific reports. 2018;8(1):17981.
Mojahed FH, Aalami AH, Pouresmaeil V, Amirabadi A, Rad MQ, Sahebkar A. Research Article Clinical Evaluation of the Diagnostic Role of MicroRNA-155 in Breast Cancer. 2020.
Alavanda C, Dirimtekin E, Mortoglou M, Arslan Ates E, Guney AI, Uysal-Onganer P. BRCA Mutations and MicroRNA Expression Patterns in the Peripheral Blood of Breast Cancer Patients. ACS Omega. 2024;9(15):17217-28.
Grimaldi AM, Incoronato M. Clinical translatability of “identified” circulating miRNAs for diagnosing breast cancer: overview and update. Cancers. 2019;11(7):901.
Tang F, Chu L, Shu W, He X, Wang L, Lu M. Selection and validation of reference genes for quantitative expression analysis of miRNAs and mRNAs in Poplar. Plant Methods. 2019;15:35.
Diansyah MN, Prayogo AA, Sedana MP, Savitri M, Zaky Romadhon P, Niken Ayu Amrita P, et al. Early detection breast cancer: role of circulating plasma miRNA-21 expression as a potential screening biomarker. Turk J Med Sci. 2021;51(2):562-9.
Savitri M, Bintoro U, Sedana M, Muhammad M, Zaky Romadhon P, Amrita P, et al. Circulating Plasma miRNA-21 as a Superior Biomarker Compared to CA 15-3: Assessment in Healthy Age Matched Subjects and Different Stage of Breast Cancer Patients. The Indonesian Biomedical Journal. 2020;12:157-64.
Chen H, Liu H, Zou H, Chen R, Dou Y, Sheng S, et al. Evaluation of Plasma miR-21 and miR-152 as Diagnostic Biomarkers for Common Types of Human Cancers. J Cancer. 2016;7(5):490-9.
Gareev I, Beylerli O, Liang Y, Xiang H, Liu C, Xu X, et al. The Role of MicroRNAs in Therapeutic Resistance of Malignant Primary Brain Tumors. Front Cell Dev Biol. 2021;9:740303.
Wang H, Tan Z, Hu H, Liu H, Wu T, Zheng C, et al. microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1. BMC cancer. 2019;19(1):738.
Wang F, Wang J, Zhang H, Fu B, Zhang Y, Jia Q, Wang Y. Diagnostic value of circulating miR-155 for breast cancer: a meta-analysis. Front Oncol. 2024;14:1374674.
Hosseini Mojahed F, Aalami AH, Pouresmaeil V, Amirabadi A, Qasemi Rad M, Sahebkar A. Clinical Evaluation of the Diagnostic Role of MicroRNA-155 in Breast Cancer. Int J Genomics. 2020;2020:9514831.
Altrawy A, Talaat RM, Nasr GM, Badr EAE, Arneth R, Arneth B, Sabit H. Diagnostic and Prognostic Roles of miR-155 and miR-3173 in Breast and Ovarian Cancer: Implications for Early Detection and Personalized Treatment. Biomedicines. 2025;13(7):1604.
Tian S, Wang J, Zhang F, Wang D. Comparative Analysis of microRNA Binding Site Distribution and microRNA-Mediated Gene Expression Repression of Oncogenes and Tumor Suppressor Genes. Genes (Basel). 2022;13(3).
de Miranda FS, Slaibi-Filho J, Calasans Dos Santos G, Carmo NT, Kaneto CM, Borin TF, et al. MicroRNA as a promising molecular biomarker in the diagnosis of breast cancer. Front Mol Biosci. 2024;11:1337706.
Desouky E, Khaliefa A, Hozayen W, Shaaban S, Hasona N. Signature of miR-21 and MEG-2 and their correlation with TGF-β signaling in breast cancer. Human & Experimental Toxicology. 2023;42:09603271231159799.
Ali M, El Gayar D, Hany N, Ezzat AH, Zeyada R. MicroRNA 21 and microRNA 10b: early diagnostic biomarkers of breast cancer in Egyptian females. Journal of the Egyptian National Cancer Institute. 2022;34(1):16.
Yu X, Liang J, Xu J, Li X, Xing S, Li H, et al. Identification and Validation of Circulating MicroRNA Signatures for Breast Cancer Early Detection Based on Large Scale Tissue-Derived Data. jbc. 2018;21(4):363-70.
Alnoaimi, Faten and Ozaslan, Mehmet. "Evaluation of hsa-miR-155-5p as a diagnostic biomarker in breast cancer and identification of its potential target genes" Oncologie, vol. 28, no. 1, 2026, pp. 187-198.
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Journal of Contemporary Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
